Non-coding RNAs in celiac disease

IF 3.2 3区医学 Q2 MEDICAL LABORATORY TECHNOLOGY

Clinica Chimica Acta Pub Date : 2025-06-06 DOI:10.1016/j.cca.2025.120417

Asma Vafadar , Elham Shirazi-Tehrani , Parisa Vosough , Shayan Khalili Alashti , Hossein Kargar Jahromi , Kamran Bagheri Lankarani , Amir Savardashtaki , Sajad Ehtiati

{"title":"Non-coding RNAs in celiac disease","authors":"Asma Vafadar , Elham Shirazi-Tehrani , Parisa Vosough , Shayan Khalili Alashti , Hossein Kargar Jahromi , Kamran Bagheri Lankarani , Amir Savardashtaki , Sajad Ehtiati","doi":"10.1016/j.cca.2025.120417","DOIUrl":null,"url":null,"abstract":"<div><div>Celiac disease (CeD) is a prevalent gluten-induced autoimmune condition that affects approximately 1%-2% of the global population. Recent research has emphasized the pivotal role of non-coding RNAs (ncRNAs) in regulating inflammatory responses and modulating autoimmune processes. This diverse group contains microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs),and serves as critical regulators in various physiological and disease-related pathways.A group of validated non-coding RNAs have emerged as promising biomarkers forthe diagnosis and treatment ofCeD.This review aims to elucidate the pathogenesis of CeD and investigate the potential of miRNAs, lncRNAs, and circRNAs as diagnostic biomarkers for this condition. By doing so, we hope to offer valuable insights into the underlying mechanisms of CeD and demonstrate the utility of ncRNAs as diagnostic and therapeutic tools in managing this autoimmune disorder.</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"576 ","pages":"Article 120417"},"PeriodicalIF":3.2000,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinica Chimica Acta","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0009898125002967","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Celiac disease (CeD) is a prevalent gluten-induced autoimmune condition that affects approximately 1%-2% of the global population. Recent research has emphasized the pivotal role of non-coding RNAs (ncRNAs) in regulating inflammatory responses and modulating autoimmune processes. This diverse group contains microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs), and serves as critical regulators in various physiological and disease-related pathways. A group of validated non-coding RNAs have emerged as promising biomarkers for the diagnosis and treatment of CeD. This review aims to elucidate the pathogenesis of CeD and investigate the potential of miRNAs, lncRNAs, and circRNAs as diagnostic biomarkers for this condition. By doing so, we hope to offer valuable insights into the underlying mechanisms of CeD and demonstrate the utility of ncRNAs as diagnostic and therapeutic tools in managing this autoimmune disorder.

查看原文本刊更多论文

乳糜泻中的非编码rna

乳糜泻（CeD）是一种普遍的麸质诱导的自身免疫性疾病，影响全球约1%-2%的人口。最近的研究强调了非编码rna （ncRNAs）在调节炎症反应和调节自身免疫过程中的关键作用。这个多样化的群体包含microRNAs （miRNAs）、长链非编码rna （lncRNAs）和环状rna (circRNAs)，并在各种生理和疾病相关途径中发挥关键调节作用。一组经过验证的非编码rna已成为诊断和治疗CeD的有希望的生物标志物。本综述旨在阐明CeD的发病机制，并探讨mirna、lncrna和circrna作为该疾病诊断生物标志物的潜力。通过这样做，我们希望对CeD的潜在机制提供有价值的见解，并证明ncrna作为诊断和治疗工具在管理这种自身免疫性疾病中的效用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinica Chimica Acta 医学-医学实验技术

CiteScore

10.10

自引率

2.00%

发文量

1268

审稿时长

23 days

期刊介绍： The Official Journal of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Clinica Chimica Acta is a high-quality journal which publishes original Research Communications in the field of clinical chemistry and laboratory medicine, defined as the diagnostic application of chemistry, biochemistry, immunochemistry, biochemical aspects of hematology, toxicology, and molecular biology to the study of human disease in body fluids and cells. The objective of the journal is to publish novel information leading to a better understanding of biological mechanisms of human diseases, their prevention, diagnosis, and patient management. Reports of an applied clinical character are also welcome. Papers concerned with normal metabolic processes or with constituents of normal cells or body fluids, such as reports of experimental or clinical studies in animals, are only considered when they are clearly and directly relevant to human disease. Evaluation of commercial products have a low priority for publication, unless they are novel or represent a technological breakthrough. Studies dealing with effects of drugs and natural products and studies dealing with the redox status in various diseases are not within the journal''s scope. Development and evaluation of novel analytical methodologies where applicable to diagnostic clinical chemistry and laboratory medicine, including point-of-care testing, and topics on laboratory management and informatics will also be considered. Studies focused on emerging diagnostic technologies and (big) data analysis procedures including digitalization, mobile Health, and artificial Intelligence applied to Laboratory Medicine are also of interest.